Conjunctivitis, Allergic: all 231 studies
Page 3 of 3. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.
- Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP UnitsCompletedNCT00718744Phase 2
- A Comparison of Olopatadine and Fluticasone in Patients With Allergic ConjunctivitisCompletedNCT00655109Phase 4
- Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SARCompletedNCT00574379Phase 2
- A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic RhinoconjunctivitisCompletedNCT00574223Phase 2
- Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal KeratoconjunctivitisCompletedNCT00567918Phase 3
- Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal KeratoconjunctivitisCompletedNCT00567762Phase 3
- Efficacy and Safety of Grass Pollen Sublingual ImmunotherapyCompletedNCT00567346Phase 2/3
- Montelukast as a Controller of Atopic SyndromeCompletedNCT00559546Phase 4
- Efficacy-safety Study of Sublingual Immunotherapy With Depigmented-polymerized Pollen Extracts to Treat RhinoconjunctivitisCompletedNCT00550875Phase 2
- Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum PratenseCompletedNCT00501527Phase 2
- Comparison of CL Wear Between Two Allergy DropsWithdrawnNCT00489398Phase 4
- Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic ConjunctivitisCompletedNCT00445874Phase 3
- Lactobacillus Rhamnosus GG Oral Treatment Efficacy on Vernal Keratoconjunctivitis TreatmentCompletedNCT00445120Phase 2/3
- Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot StudyStatus unknownNCT00443105Phase 2
- Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic ConjunctivitisCompletedNCT00432757Phase 3
- Cyclosporin A Eye Drop Treatment in Vernal KeratoconjunctivitisCompletedNCT00426023Phase 3
- Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic ConjunctivitisCompletedNCT00423007Phase 3
- Twin SUBLIVAC® Grasses Clinical Efficacy StudyCompletedNCT00422149Phase 3
- Normal Values of Facial ThermographyCompletedNCT00411606
- Mast-Cell Stabilizing Effects of OlopatadineCompletedNCT00389025Phase 4
- A Study Of The Safety And Effectiveness Of A New Treatment For Allergic ConjunctivitisWithdrawnNCT00375596Phase 2
- Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic ConjunctivitisCompletedNCT00364091Phase 3
- Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal KeratoconjunctivitisCompletedNCT00357019Phase 4
- Olopatadine 0.2% for the Treatment of Allergic ConjunctivitisCompletedNCT00331500Phase 3
- A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)CompletedNCT00311844Phase 4
- Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008Status unknownNCT00298337Phase 2/3
- Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-GlucanTerminatedNCT00276445Phase 4
- Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic ConjunctivitisCompletedNCT00244543Phase 3
- Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic ConjunctivitisCompletedNCT00241319Phase 3
- Safety Study of Ophthalmic Solution in Healthy, Normal VolunteersCompletedNCT00223951Phase 3
- Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic ConjunctivitisCompletedNCT00133627Phase 4